Chengdu Olymvax Biopharmaceuticals Inc. A
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was fou… Read more
Market Cap & Net Worth: Chengdu Olymvax Biopharmaceuticals Inc. A (688319)
Chengdu Olymvax Biopharmaceuticals Inc. A (SHG:688319) has a market capitalization of $1.73 Billion (CN¥12.70 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #7093 globally and #1171 in its home market, demonstrating a 6.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chengdu Olymvax Biopharmaceuticals Inc. A's stock price CN¥31.31 by its total outstanding shares 405708900 (405.71 Million).
Chengdu Olymvax Biopharmaceuticals Inc. A Market Cap History: 2021 to 2026
Chengdu Olymvax Biopharmaceuticals Inc. A's market capitalization history from 2021 to 2026. Data shows change from $1.97 Billion to $1.73 Billion (-4.88% CAGR).
Chengdu Olymvax Biopharmaceuticals Inc. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chengdu Olymvax Biopharmaceuticals Inc. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.00x
Chengdu Olymvax Biopharmaceuticals Inc. A's market cap is 1.00 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
28.24x
Chengdu Olymvax Biopharmaceuticals Inc. A's market cap is 28.24 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.97 Billion | $487.15 Million | $107.96 Million | 4.05x | 18.27x |
| 2022 | $763.87 Million | $547.48 Million | $26.58 Million | 1.40x | 28.74x |
| 2023 | $870.16 Million | $496.12 Million | $17.56 Million | 1.75x | 49.57x |
| 2024 | $586.12 Million | $588.86 Million | $20.76 Million | 1.00x | 28.24x |
Competitor Companies of 688319 by Market Capitalization
Companies near Chengdu Olymvax Biopharmaceuticals Inc. A in the global market cap rankings as of March 18, 2026.
Key companies related to Chengdu Olymvax Biopharmaceuticals Inc. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Chengdu Olymvax Biopharmaceuticals Inc. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Chengdu Olymvax Biopharmaceuticals Inc. A's market cap moved from $1.97 Billion to $ 1.73 Billion, with a yearly change of -4.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.73 Billion | +23.46% |
| 2025 | CN¥1.40 Billion | +139.25% |
| 2024 | CN¥586.12 Million | -32.64% |
| 2023 | CN¥870.16 Million | +13.92% |
| 2022 | CN¥763.87 Million | -61.27% |
| 2021 | CN¥1.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Chengdu Olymvax Biopharmaceuticals Inc. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.73 Billion USD |
| MoneyControl | $1.73 Billion USD |
| MarketWatch | $1.73 Billion USD |
| marketcap.company | $1.73 Billion USD |
| Reuters | $1.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.